Request Demo
Cabaletta Bio to Attend Investor Conferences in September
30 August 2024
PHILADELPHIA, Aug. 28, 2024 — Cabaletta Bio, Inc., listed on Nasdaq as CABA, is a clinical-stage biotechnology company pioneering targeted cell therapies specifically for patients suffering from autoimmune diseases. The company has announced its participation in several key investor conferences scheduled for September.
Cabaletta Bio will be joining the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is planned for Wednesday, September 4, 2024, at 4:50 p.m. ET. The following day, the company will participate in the 2024 Wells Fargo Healthcare Conference in Boston, MA, with another fireside chat at 8:00 a.m. ET on Thursday, September 5, 2024.
On Wednesday, September 11, 2024, Cabaletta Bio will join the H.C. Wainwright 26th Annual Global Investment Conference, also held in New York, NY, with a fireside chat scheduled for 9:00 a.m. ET. The company’s final participation for the month will be at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY. This event will feature a fireside chat on Tuesday, September 17, 2024, at 11:30 a.m. ET.
For those unable to attend in person, Cabaletta Bio will provide live webcasts of each presentation. These webcasts will be accessible through the News and Events section of the company’s website at www.cabalettabio.com, with replays available for a duration of 30 days.
Cabaletta Bio is devoted to the discovery and development of engineered T cell therapies aimed at offering deep, durable, and potentially curative treatments for autoimmune diseases. The company utilizes the CABA™ platform, which includes two primary therapeutic strategies: CARTA and CAART.
The CARTA strategy includes CABA-201, a fully human CD19-CAR T cell containing 4-1BB, which is currently the lead product candidate. CABA-201 is being evaluated in the RESET™ clinical trials targeting diseases such as myositis, systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. Additionally, it is being tested in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial, specifically for pemphigus vulgaris.
The CAART strategy features multiple clinical-stage candidates, among them DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. These strategies are part of Cabaletta Bio’s broader objective to develop therapies that can provide long-term relief and potentially cure various autoimmune diseases.
Cabaletta Bio is headquartered in Philadelphia, PA, where it also conducts its lab operations.
Cabaletta Bio will be joining the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is planned for Wednesday, September 4, 2024, at 4:50 p.m. ET. The following day, the company will participate in the 2024 Wells Fargo Healthcare Conference in Boston, MA, with another fireside chat at 8:00 a.m. ET on Thursday, September 5, 2024.
On Wednesday, September 11, 2024, Cabaletta Bio will join the H.C. Wainwright 26th Annual Global Investment Conference, also held in New York, NY, with a fireside chat scheduled for 9:00 a.m. ET. The company’s final participation for the month will be at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY. This event will feature a fireside chat on Tuesday, September 17, 2024, at 11:30 a.m. ET.
For those unable to attend in person, Cabaletta Bio will provide live webcasts of each presentation. These webcasts will be accessible through the News and Events section of the company’s website at www.cabalettabio.com, with replays available for a duration of 30 days.
Cabaletta Bio is devoted to the discovery and development of engineered T cell therapies aimed at offering deep, durable, and potentially curative treatments for autoimmune diseases. The company utilizes the CABA™ platform, which includes two primary therapeutic strategies: CARTA and CAART.
The CARTA strategy includes CABA-201, a fully human CD19-CAR T cell containing 4-1BB, which is currently the lead product candidate. CABA-201 is being evaluated in the RESET™ clinical trials targeting diseases such as myositis, systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. Additionally, it is being tested in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial, specifically for pemphigus vulgaris.
The CAART strategy features multiple clinical-stage candidates, among them DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. These strategies are part of Cabaletta Bio’s broader objective to develop therapies that can provide long-term relief and potentially cure various autoimmune diseases.
Cabaletta Bio is headquartered in Philadelphia, PA, where it also conducts its lab operations.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.